Previous studies have identified several subgroups of CD8+ T cells responsible of anti-tumor effect in tumor-killing process [15, 16], which implicated our current exploration on whether the subgroup of CD38+ CD8+ T cells also act as a member involved in tumor-killing process, in the hope of helping improve the success rate of immunotherapy for lung cancer patients [17]. The gene discussed is CD38; the disease is lung carcinoma.